Information Systems
ABOUT AMGEN
Amgen harnesses the best of biology and technology to fight the world’s toughest diseases, and make people’s lives easier,fullerand longer. We discover, develop,manufactureand deliver innovative medicines to help millions of patients. Amgen helpedestablishthe biotechnology industry more than 40 years ago andremainson thecutting-edgeof innovation, using technology and human genetic data to push beyondwhat’sknown today.
ABOUT THE ROLE
We are seeking an AI Adoption Engineer who will serve as the technical catalyst for accelerating enterprise adoption of AI technologies including ChatGPT, Codex, AI agents, prompt engineering, and AI-enabled development workflows.
Key Responsibilities
Drive adoption of ChatGPT, GitHub Copilot, Codex, and other AI tools while building reusable AI solutions, agents, and workflow automations.
Conduct technical workshops, mentor teams on AI best practices, and collaborate with Product and Engineering to scale AI adoption.
support multiple cross functional teams on use case execution with AI tools (codex and ChatGPT work)
Evaluate emerging AI technologies, develop proof of concepts, and measure AI adoption and productivity improvements.
This role combines hands-on software engineering with technical consulting, enablement, and innovation
Required Qualification:
Bachelor's or Master's degree in Computer Science, AI, Machine Learning, or a related field.
8 to 12 years of software engineering, AI, or machine learning experience.
Strong Python programming and REST API development experience.
Hands-on experience with LLMs, ChatGPT, GitHub Copilot, Codex, Claude, or similar AI tools.
Experience building AI-powered applications and workflow automation.
Knowledge of prompt engineering and AI enablement practices.
Excellent communication, technical mentoring, and stakeholder management skills
Good-to-Have Skills:
Experience with ChatGPT Enterprise, custom GPTs or comparable generative AI platforms.
Experience supporting technology adoption through training, office hours or communities of practice.
Familiarity with responsible AI, privacy, informationsecurityor access management.
Experience in biotechnology, pharmaceuticals,healthcareoranother regulated industry
EQUAL OPPORTUNITY STATEMENT:
Amgen is an Equal Opportunity employer and will consider you without regard to your race, color, religion, sex, sexual orientation, gender identity, national origin, protected veteran status, or disability status.
Amgen harnesses the best of biology and technology to fight the world’s toughest diseases, and make people’s lives easier, fuller and longer. We helped establish the biotechnology industry, and we remain on the cutting-edge of innovation, using technology and human genetic data to push beyond what’s known today. Our investment in research and development has yielded a robust pipeline that builds on our existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases.
Amgen is one of 30 companies comprising the Dow Jones Industrial Average®, and part of the Nasdaq-100 Index®. In 2024, Amgen was named one of the “World’s Most Innovative Companies” by Fast Company and one of “America’s Best Large Employers” by Forbes.
For more information, visit Amgen.com and follow us on X, LinkedIn, Instagram, TikTok, YouTube and Threads.
🔗 Community Guidelines: https://wwwext.amgen.com/community-guidelines
🔗Global Privacy Statement Directory: www.amgen.com/dp
Special Advisory: Please be cautious of scam recruitment offers claiming to be from Amgen. Such scams may come from various sources, including fake websites and/or unsolicited emails and seek to obtain personal data or payment from victims by offering jobs that do not exist. Please be advised that Amgen would never ask for payment to progress a job application. When in doubt, please check to see if the position in question is posted on this website before applying. Additionally, please report any suspicious recruiting activity to https://complaint.ic3.gov/ and thank you for your assistance.
